Metabolic syndrome and liver steatosis: Clinical and laboratory correlations
Summary. Metabolically associated fatty liver disease (MAFLD) is closely associated with cardiometabolic polymorbidity, which determines an unfavorable prognosis and high risk of cardiovascular events in patients. The aim: to compare clinical, demographic, and comorbid conditions in patients with MAFLD and control individuals without this disease who sought medical help in a tertiary medical center. Material and methods. Current retrospective “case – control” study included 850 participants: 432 patients diagnosed with MAFLD and 418 controls, matched for gender and age. Anthropometric, laboratory, and instrumental data, as well as comorbidity patterns, were assessed. Results. Patients with MAFLD were characterized by significantly higher body mass index (p <0.001) and transaminase levels (p <0.001). In the MAFLD group, type 2 diabetes mellitus (49.3 vs. 35.9%; odds ratio 1.74; p <0.001) and dyslipidemia (69.0 vs. 42.3%; odds ratio 3.03; p <0.001) were significantly more common. A direct correlation was established between the degree of liver steatosis and the number of metabolic comorbidities (from 0.82 at grade 0 to 3.82 at grade 3 steatosis; p <0.001). The level of liver stiffness positively correlated with the body mass index, fasting glucose and triglyceride levels (p <0.001). The revealed clustering of MAFLD with type 2 diabetes mellitus and dyslipidemia confirms the role of insulin resistance in the pathogenesis of the disease and reflects its systemic nature. Direct correlation between the severity of steatosis and multimorbidity and cytolysis syndrome determines the advisability of routine screening and multidisciplinary management of such kind of patients. Conclusion. MAFLD is associated with a significant cumulative metabolic burden. Increasing steatosis and liver stiffness are associated with a progressive deterioration of the carbohydrate and lipid profile, necessitating comprehensive control of cardiometabolic risk factors to prevent disease progression.T.A. Turankova, N.Yo. Shanka, Ch.S. Pavlov
Keywords
metabolically associated fatty liver disease
liver steatosis
comorbidity
metabolic syndrome
type 2 diabetes mellitus
dyslipidemia
References
1. Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z et al. From NAFLD to MAFLD: Implications of a premature change in terminology. Hepatology. 2021;73(3):1194–98.
PMID: 32544255. https://doi.org/10.1002/hep.31420
2. Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919.
PMID: 33006093. https://doi.org/10.1007/s12072-020-10094-2
3. Eslam M, Ahmed A, Despres JP, Dixon JB, Foufelle F, Gastaldelli A et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol. 2021;6(9):743–53.
PMID: 34265276. https://doi.org/10.1016/S2468-1253(21)00132-1
4. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
PMID: 28930295. https://doi.org/10.1038/nrgastro.2017.109
5. Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus – mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599–612.
PMID: 33972770. https://doi.org/10.1038/s41575-021-00448-y
6. Pezzoli A, Abenavoli L, Scarcella M, Rasetti C, Svegliati Baroni G, Tack J, Scarpellini E. The management of cardiometabolic risk in MAFLD: Therapeutic strategies to modulate deranged metabolism and cholesterol levels. Medicina (Kaunas). 2025;61(3):387.
PMID: 40142198; PMCID: PMC11944025. https://doi.org/10.3390/medicina61030387
7. Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72(4):785–801.
PMID: 32059982. https://doi.org/10.1016/j.jhep.2020.01.013
8. Райхельсон К.Л., Маевская М.В., Жаркова М.С., Гречишникова В.Р., Оковитый С.В., Деева Т.А. с соавт. Жировая болезнь печени: новая номенклатура и ее адаптация в Российской Федерации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(2):35–44. (Raikhelson KL, Maevskaya MV, Zharkova MS, Grechishnikova VR, Okovityi SV, Deeva TA et al. Steatotic liver disease: New nomenclature and its localization in the Russian Federation. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(2):35–44. (In Russ.)).
EDN: RVLEHF. https://doi.org/10.22416/1382-4376-2024-961
9. Ивашкин В.Т., Драпкина О.М., Маев И.В., Трухманов А.С., Блинов Д.В., Пальгова Л.К. с соавт. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;25(6):31–41. (Ivashkin VT, Drapkina OM, Mayev IV, Trukhmanov AS, Blinov DV, Palgova LK et al. Prevalence of non-alcoholic fatty liver disease in outpatients of the Russian Federation: DIREG 2 study results. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(6):31–41 (In Russ.)). EDN: VOXFQP.
10. Павлов Ч.С., Туранкова Т.А., Теплюк Д.А., Мудрова А.В., Успенский Ю.П., Мехтиев С.Н. с соавт. Возможности комбинированной терапии хронических заболеваний печени – результаты многоцентрового исследования «ПРОМЕТЕЙ». Доказательная гастроэнтерология. 2025;14(3):56–68. (Pavlov ChS, Turankova TA, Teplyuk DA, Mudrova AV, Uspenskiy YuP, Mekhtiev SN et al. Opportunities of combination therapy for chronic liver diseases: Results of the multicenter PROMETHEUS study. Dokazatel'naya gastroenterologiya = Russian Journal of Evidence Based Gastroenterology. 2025;14(3):56–68 (In Russ.)).
EDN: OUVGWF. https://doi.org/10.17116/dokgastro20251403156
11. Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Распространенность неалкогольной жировой болезни печени в России: метаанализ. Consilium Medicum. 2023;25(5):313–319. (Maev IV, Andreev DN, Kucheryavyy YA. Prevalence of non-alcoholic fatty liver disease in Russia: A meta-analysis. Consilium Medicum 2023;25(5):313–319 (In Russ.)).
EDN: BNGAZT. https://doi.org/10.26442/20751753.2023.5.202155
12. Sheptulina A., Liusina E., Demianova A., Gubanova A., Vorobova, V, Novitskaia E et al. Depression, anxiety, and comorbidities as key factors associated with fatigue in MASLD: Insights from a nationwide study (Poster presentation). EASL SLD Meeting. 2026.
13. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology. 2011;54(3):1082–90.
PMID: 21618575. PMCID: PMC4197002. https://doi.org/10.1002/hep.24452
14. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58(5):1007–19.
PMID: 23183525. https://doi.org/10.1016/j.jhep.2012.11.021
15. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557–65.
PMID: 28130788. PMCID: PMC5397356. https://doi.org/10.1002/hep.29085
16. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.
PMID: 28714183. https://doi.org/10.1002/hep.29367
17. Segura-Azuara NLA, Varela-Chinchilla CD, Trinidad-Calderon PA. MAFLD/NAFLD biopsy-free scoring systems for hepatic steatosis, NASH, and fibrosis diagnosis. Front Med (Lausanne). 2022;8:774079.
PMID: 35096868. PMCID: PMC8792949. https://doi.org/10.3389/fmed.2021.774079
18. Younossi ZM, de Avila L, Petta S, Hagstrom H, Kim SU et al.; Global NASH/MASH Council (GNC). Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study. Hepatology. 2025. Online ahead of print.
PMID: 41231627. https://doi.org/10.1097/HEP.0000000000001617
19. Feng G, Targher G, Byrne CD, Yilmaz Y, Wai-Sun Wong V, Adithya Lesmana CR et al. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep. 2024;7(3):101271.
PMID: 39980749. PMCID: PMC11840544. https://doi.org/10.1016/j.jhepr.2024.101271
20. Xu MR, Li MH, Zhang YW, Lu JX, Li LX, Zhang YR. The burden of multiple metabolic diseases and their impact on cardiovascular and kidney complications in type 2 diabetes: A 10-year real-world study. Diabetes Metab Syndr Obes. 2025;18:3717–30.
PMID: 41058759. PMCID: PMC12499592. https://doi.org/10.2147/DMSO.S548509
21. Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int. 2021;41(6):1290–93.
PMID: 33590934. https://doi.org/10.1111/liv.14828
22. (Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): A multisystemic disease beyond the liver. Zhonghua Gan Zang Bing Za Zhi. 2025;33(1):77–87 (In Chinese)).
PMID: 39929687. https://doi.org/10.3760/cma.j.cn501113-20250103-00003
23. Qu B, Li Z. Exploring non-invasive diagnostics for metabolic dysfunction-associated fatty liver disease. World J Gastroenterol. 2024;30(28):3447–51.
PMID: 39091712. PMCID: PMC11290396. https://doi.org/10.3748/wjg.v30.i28.3447
24. Imai J, Takashimizu S, Suzuki N, Ohshinden K, Sawamoto K, Mishima Y et al. Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD. Sci Rep. 2024;14(1):13411.
PMID: 38862756. PMCID: PMC11166940. https://doi.org/10.1038/s41598-024-64301-3
About the Authors
Taisiia A. Turankova, MD, assistant at the Department of therapy of the Institute of Professional Education,I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.
E-mail: turankova.ta@gmail.com
ORCID: https://orcid.org/0000-0001-8441-7396. eLibrary SPIN: 5631-8691. Scopus ID: 57218197799
Nebyu Yo. Shanka, MD, postgraduate student of the Department of therapy of the Institute of professional education, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.
E-mail: nebyu.yonas69@gmail.com
ORCID: https://orcid.org/0009-0007-6870-1822. Scopus ID: 59539626300
Chavdar S. Pavlov, MD, Dr. Sci. (Medicine), professor, head of the Department of therapy of the Institute of professional education, deputy director for scientific and organizational work of N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University); leading researcher at S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow, Russian Federation
E-mail: chpavlov@mail.ru
ORCID: https://orcid.org/0000-0001-5031-9798. eLibrary SPIN: 5052-9020. Scopus ID: 57218197799
Similar Articles
